Drug interactions between antibiotics and select maintenance medications: Seeing more clearly through the narrow therapeutic window of opportunity

Consultant Pharmacist

Volumn 19, Issue 12, 2004, Pages 1119-1128

  Regal, Randolph E ^a   Vue, Celina Ong ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Antibiotics; Carbamazepine; Cyclosporine; Digoxin; Drug interactions; Phenytoin; Rifompin; Tacrolimus; Warfarin

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; CARBAMAZEPINE; CEFOTETAN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DISULFIRAM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; GRISEOFULVIN; HYPERICUM PERFORATUM EXTRACT; ISONIAZID; METRONIDAZOLE; NAFCILLIN; NORFLOXACIN; OFLOXACIN; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PYRROLE DERIVATIVE; RIFAMPICIN; THEOPHYLLINE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; AGITATION; APNEA; ASTHMA; ATAXIA; BLEEDING; CHRONIC BRONCHITIS; COMA; COMPLEX PARTIAL SEIZURE; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAND MAL SEIZURE; HEADACHE; HEMATURIA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPROTHROMBINEMIA; HYPOTENSION; MAINTENANCE THERAPY; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NYSTAGMUS; REVIEW; SEIZURE; SIDE EFFECT; SLURRED SPEECH; TACHYCARDIA; TREMOR;

EID: 11144251740     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.1119     Document Type: Review

References (56)

1. Michalets EL. Update: clinically significant cytochrome p-450 drug interactions. Pharmacotherapy 1998;8:84-112.
2. Omiecinski CJ, Remmel RP, Hosagrahara VP. Concise review of the cytochrome p450s and their roles in toxicology. Toxicological Sciences 1999;48:151-6.
3. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865-75.
4. Hirsh J, Dalen JE, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:s8-s21.
5. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000;63:28-31.
6. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295:354-7.
7. Kaufman JM, Fauver HE Jr. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology 1980;16:601-3.
8. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-5.
9. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000;34:495-513.
10. Piscitelli SC, Rodvold KA. eds. Drug Interactions in Infectious Diseases. Totowa, NJ:. Humana Press;2000.
11. Baciewicz AM, Menke JJ, Bokar JA et al. Fluconazole-warfarin interaction. Ann Pharmacother 1994;28:1111.
12. Black DJ, Kunze KL, Wienkers LC et al. Warfarin-fluconazole. II.: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8.
13. Albengres E, Le Louet H, Tillement J-P. Systemic antifungal agents: drug interactions of clinical significance. Drug Safety 1998; 18:83-97.
14. Purkins L, Wood N, Kleinermans D et al. Voriconazole potentiates warfarin induced prothrombin time prolongation. J Clin Pharmacol 2003;56:24-9.
15. Leor J, Matetzki S. Ofloxacin and warfarin (letter). Ann Intern Med 1988;109:761.
16. Linville T, Matanin D. Norfloxacin and warfarin (letter). Ann Intern Med 1989; 110:751-2.
17. Kamada AK. Possible interaction between ciprofloxacin and warfarin. Ann Pharmacother 1990;24:27-8.
18. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000;63:28-31
19. Gheno G, Cinetto L. Levofloxacin-warfarin interaction. Eur J Clin Pharmacol 2001;57:427.
20. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacotherapy 2002;36:1554-7.
21. Liao S, Palmer M, Fowler C et al. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Phar 1996;36: 1072-7.
22. Aminimanizani A, Beringer P, Jeliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40:169-87.
23. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992;14:272-84
24. Shearer MJ, Bechtold H, Andrassy K et al. Mechanism of cephalosporin-induced hypo-prothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988;28:88-95.
25. Conjura A, Bell W, Lipsky JJ. Cefotetan and hypoprothrombinemia. Ann Intern Med 1988;103:643.
26. Cohen H, Mackie IJ, Walshe K et al. The effects of cefotetan disodium on haemostasis. J Hosp Infect 1987;10:51-57.
27. Ward A, Richards DM. Cefotetan: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1985;30:382-426.
28. Conly J, Stein K. Reduction of vitamin K-2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994;17:531-9.
29. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003;37: 367-9.
30. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997;29:1129-88.
31. Jensen JC, Gugler R. Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther 1985; 37:407-10.
32. Cadle RM, Zenon III GJ, Rodriguez-Barradas MC et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994;28:191-4.
33. Gillum JG, Israel DS, Scott RB et al. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1996;40:1715-6.
34. Wiggins J, Arbab O, Ayres JG et al. Elevated serum theophylline concentration following cessation of erythromycin treatment. Eur J Resp Dis 1986;68:298-300.
35. Paulsen O, Hoglund P, Nilsson LG et al. The interaction of erythromycin with theophylline. Eur Clin Pharmacol 1987;32:493-3.
36. Package insert. Biaxin (clarithromycin). North Chicago, IL: Abbott Laboratories; June 2002.
37. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996;37:s133-s142.
38. Sud K, Singh B, Krishna VS et al. Unpredictable cyclosporine-fluconazole interaction in renal transplant recipients. Nephrol Dialysis Transplant 1999;4:1698-703.
39. Macias MO, Salvador P, Jurtado J et al. Tacrolimus-itraconazole interaction in a kidney transplant patient (letter). Ann Pharmacother 2000;34:536.
40. Mahnke CB, Sutton RM, Venkataramanan R et al.Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant 2003;7:474-8.
41. Freeman DJ, Martell R, Carruthers SG et al. Cyclosporine-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987;23:776-8.
42. Murray BM, Edwards L, Morse GD et al. Clinically important interaction of cyclosporine and erythromycin. Transplantation 1987;43:602-4.
43. Stamatakis MK, Richards JG. Interaction between quinupristin/daltopristin and cyclosporine. Ann Pharmacother 1997; 31:576-8.
44. Elphick M. The clinical uses and pharmacology of carbamazepine in psychiatry. Int Clin Psychopharmacol 1988;3:185-203.
45. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983;33:460-4.
46. Finch CK, Green CA, Self TH. Fluconazole-carbamazepine interaction. South Med J 2002;95:1099-100.
47. Nair DR, Morris HH. Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother 1999;33:790-2.
48. Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III. Arch Intern Med 1997;157:2453-8.
49. Barbarash RA, Bauman JL, Fischer JH et al. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest 1988;94:954-9.
50. Gault H, Longerich L, Dawe M et al. Digoxin-rifampin interaction. Clin Pharmacol Ther 1984;35:750-4.
51. Freitag VL, Skifton RD, Lake KD. Effect of short-term rifampin on stable cyclosporine concentrations. Ann Pharmacother 1999;33: 871-2.
52. Lee CR, Thrasher KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 2001;21:1240-6.
53. Qureshi GD, Reinders TP, Somori GJ et al. Warfarin resistance with nafcillin therapy. Ann Intern Med 1984;100:527-9.
54. Taylor AT, Pritchard DC, Goldstein AO et al. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994;39:182-5.
55. Veremis SA, Maddux MS, Pollak R et al. Subtherapeutic cyclosporine concentrations during nafcillin therapy. Transplantation 1987;43:913-4.
56. MICROMEDEX® Healthcare Series Vol. 120. 2004.